Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
COMBINATION THERAPIES FOR TREATING CANCERS
Document Type and Number:
WIPO Patent Application WO/2018/218633
Kind Code:
A1
Abstract:
Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.

Inventors:
ZHANG YIHONG (US)
WEI WANG (CN)
CHEN YIYOU (US)
Application Number:
PCT/CN2017/086911
Publication Date:
December 06, 2018
Filing Date:
June 02, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BEIJING PERCANS ONCOLOGY CO LTD (CN)
International Classes:
A61P35/00; A61K39/395
Domestic Patent References:
WO2014147573A22014-09-25
WO2016191296A12016-12-01
Other References:
THOMAS A. ET AL.: "Refining the treatment of NSCLC according to histological and molecular subtypes", NATURE REVIEWS | CLINICAL ONCOLOGY, vol. 12, no. 9, 30 September 2015 (2015-09-30), pages 511 - 526, XP055549340
ZHOU J. ET AL.: "CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma", NATURE COMMUNICATIONS, vol. 8, 6 January 2017 (2017-01-06), pages 13897, XP055549349
LUKE J.J. ET AL.: "The Biology and Clinical Development of MEK Inhibitors for Cancer", DRUGS, vol. 74, no. 18, 21 November 2014 (2014-11-21), pages 2111 - 2128
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: